(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199149 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 37/06* (2006.01)
A61K 39/39 (2006.01)

(21) International Application Number:
PCT/US2025/020439

(22) International Filing Date:
18 March 2025 (18.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/566,663 18 March 2024 (18.03.2024) US

(71) Applicant: **COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC.** [US/US]; 8045 Lamon Avenue #1202, Skokie, IL 60077 (US).

(72) Inventors: **PODOJIL, Joseph**; C/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **ELHOFY, Adam**; C/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US).

(74) Agent: **NEVILLE, Katherine, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: STING AGONISM FOR ANTIGEN SPECIFIC TOLERANCE

(57) Abstract: The present application is directed, in general, to compositions comprising antigens and cGAS-STING pathway activating agents and uses thereof to induce or enhance tolerogenic immune responses to an antigen.

WO 2025/199149 A1